La vendita allo scoperto per BFF BK SPA by BFF BK SPA dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di BFF BK SPA by BFF BK SPA. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

BFF BK SPA by BFF BK SPA (OTC:BFFBF) Azioni, Report sulle vendite allo scoperto

BFF BK SPA by BFF BK SPA

Mizuho analyst Arvind Ramnani maintains Dayforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAY#NYSE">DAY</a>) with a Outperform and lowers the price target from $95 to $80.

News

Price Target

Analyst Ratings

Mizuho Maintains Outperform on Dayforce, Lowers Price Target to $80

Jefferies analyst Julien Dumoulin-Smith maintains Sempra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRE#NYSE">SRE</a>) with a Hold and lowers the price target from $77 to $75.

Jefferies Maintains Hold on Sempra, Lowers Price Target to $75

Shareholder Update: Strengthening Business Lines Through Innovative Applications in Blue Laser Technology, Artificial Intelligence, Robotics, and Fintech Solutions
NUBURU, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURU#NYSE">BURU</a>), a leader in high-power and high-brightness industrial blue laser technology, is excited to provide a comprehensive update to its shareholders regarding its newly formulated business model canvas, which encompasses two synergistic key business lines.
Blue Laser Technology &amp; Product Development.
NUBURU is revitalizing its blue-laser technology business unit by collaborating closely with the previous management team to develop a new strategic plan aimed specifically at addressing the defense sector's needs and other few synergistic vertical applications. The recent Joint-Pursuit Agreement signifies the company's commitment to leveraging its innovative laser solutions for defense applications. This enhanced focus will also explore vertical applications of the technology, pursuing both new intellectual property (IP) rights and the strategic use of licensed IP rights.
Defense &amp; Security Hub Acquisition.
As part of its acquisition plan, NUBURU is on track to finalize the purchase of Defense &amp; Security companies, referred to herein as the "Defense &amp; Security Hub" for confidential reasons. This hub will concentrate on delivering cutting-edge products tailored for defense applications while extending its robust security solutions through a software-as-a-service (SaaS) model, effectively catering to sectors where operational resilience is a regulatory requirement. These acquisitions are projected to contribute approximately over $50 million in 2025 revenue to NUBURU, subject to U.S. GAAP accounting and contingent upon regulatory and shareholder approvals and timing of the acquisitions.
Investment &amp; Partnerships in Advanced Technologies and Innovations.
NUBURU remains committed to navigating its Transformation Plan, which emphasizes the adoption of exponential technologies, including AI and robotics, and innovative solutions which can underpin the Company' two key business lines. As a part of this plan entering into the fastest growing global industry of Artificial Intelligence, NUBURU formed a strategic partnership with COEPTIS' NexGenAI Affiliates Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COEP#NASDAQ">COEP</a>), an innovative provider of artificial intelligence and robotics solutions. NextGen's advanced platform utilizes sophisticated AI algorithms and data analytics to optimize marketing strategies, enhance customer engagement, and implement operational efficiencies. This allows NUBURU a broader goal of fostering an ecosystem where technology serves as a catalyst for growth and innovation.
Furthermore, as NUBURU has previously announced it has made a significant strategic investment in Supply@ME Capital Plc (LON:SYME) ("SYME"), a disruptive fintech platform focused on Inventory Monetisation&#xA9; solutions for manufacturing and trading companies. This allows NUBURU to continue to strengthen its operational framework to support working capital needs over its two key business lines, particularly in inventory management, as global trade dynamics and regional supply chains evolve. Also, the clients of SYME' Platform can enable cross-selling strategies with the Defense &amp; Security Hub, in particular the SaaS solutions which Nuburu will be able to offer, following the acquisitions.
Strategic Financial Management &amp; Elimination of previous debts.
As a part of this transformation, NUBURU is focused on addressing legacy issues, including the settlement of outstanding payables from previous management and enhancing its position with preferred stockholders. As a part of this tremendous transformation plan NUBURU previously announced the elimination of 100% of long-term indebtedness allowing financial flexibility for future transactions and is in the process on finalizing its final payables with a strategic funding partner.

BURU

COEP

NUBURU Announces Shareholder Update, Strengthening Business Lines Through Innovative Applications In Blue Laser Technology, AI, Robotics, And Fintech Solutions

WIIM

VERV

Verve Therapeutics shares are trading higher after Canaccord Genuity raised its price target on the stock from $32 to $39 and maintained a Buy rating.

On Tuesday, Bank of America Corp&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>)&nbsp;reported a&nbsp;first-quarter fiscal 2025&nbsp;net income of $7.4 billion (versus $6.7 billion a year ago) and EPS of $0.90, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate of $0.81</a>.
Revenue, <a target="_blank" href="https://investor.bankofamerica.com/quarterly-earnings" rel="noreferrer noopener">net of interest expense</a>, increased 6.0% year over year to $27.37 billion, beating the&nbsp;analyst consensus estimate of&nbsp;$26.99 billion. This was driven by noninterest income growth across all segments and higher net interest income (NII).
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44586154/stride-bank-partners-with-affirm-to-issue-affirm-card-enhancing-flexible-payment-options-for-consumers" rel="noreferrer noopener">Stride Bank, Affirm Issue New Debit Card With Pay-Over-Time Loans</a>
Segment Net income:&nbsp;Consumer Banking clocked $2.53 billion versus $2.66 billion Y/Y, Global Wealth and Investment Management was $1.007 billion versus $1.005 billion Y/Y, Global Banking was $1.91 billion versus $1.99 billion Y/Y, and Global Markets was $1.94 billion versus $1.79 billion Y/Y.
Investment banking fees declined by 3% to $1.5 billion.
Net interest income was $14.44 billion (+3.0% Y/Y), driven by Global Markets activity and fixed-rate asset repricing.
Noninterest income was $12.92 billion (+9.6% Y/Y). Provision for credit losses grew 12.2 Y/Y to $1.48 billion.
The efficiency ratio for the quarter was 64.59%, compared to 66.36% Y/Y. The bank reported a CET1 ratio of 11.8%, compared to 11.9% a year ago. The book value per share of $36.39 improved by 8%.
The average loan and lease balance was $1.09 trillion (+4.0% Y/Y). Average deposits are up 3% Y/Y to $1.96 trillion. Bank of America added ~1.0 million credit card accounts during the quarter.
Outlook:&nbsp;Bank of America reiterated <a target="_blank" href="https://www.benzinga.com/news/earnings/25/01/43026092/bank-of-america-q4-earnings-6-7-billion-profit-1-7-billion-in-investment-banking-fees-forecasts-higher-nii-in-2025" rel="noreferrer noopener">a fourth-quarter</a> net interest income of <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">~$15.5 billion—$15.7 billion</a>.
Bank of America stock lost over 17% year-to-date. At least five Wall Street firms <a target="_blank" href="https://www.benzinga.com/quote/BAC/analyst-ratings" rel="noreferrer noopener">reduced their price targets</a> on the stock in March.
Last week, the U.S. financial sector got some relief after President Donald Trump&nbsp;announced a <a target="_blank" href="https://www.benzinga.com/news/25/04/44720460/bank-of-america-and-wells-fargo-surge-as-bank-stocks-soar-on-tariff-pause-news" rel="noreferrer noopener">90-day suspension</a> of tariffs&nbsp;on countries that have not retaliated against U.S. trade actions. The financial sector is a high beta, as it tends to outperform when markets are bullish and underperform during risk-off conditions.
However, Ray Dalio of&nbsp;Bridgewater Associates <a target="_blank" href="https://www.benzinga.com/25/04/44777263/ray-dalio-who-predicted-the-2008-financial-crisis-warns-about-recession-as-us-china-tariff-war-escalates" rel="noreferrer noopener">expressed concerns about</a> a potential recession despite Trump&nbsp;pausing reciprocal tariffs.
Price Action:&nbsp;BAC stock is up 2.13% at $37.45 premarket at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44800514/these-gaming-stocks-are-under-pressure-as-analyst-cuts-forecast-on-macau-risk-and-soft-vegas-data" target="_blank" rel="noreferrer noopener">These Gaming Stocks Are Under Pressure As Analyst Cuts Forecast On Macau Risk And Soft Vegas Data</a></li>
</ul>
Photo via Shutterstock

Earnings

Guidance

Bank of America CEO Says Consumer Continues To Spend And Maintain Healthy Credit Quality, Sticks To Annual Outlook

Mizuho analyst Siti Panigrahi maintains Cadence Design Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) with a Outperform and lowers the price target from $350 to $300.

CDNS

Mizuho Maintains Outperform on Cadence Design Systems, Lowers Price Target to $300

DA Davidson analyst Michael Shlisky maintains Lakeland Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAKE#NASDAQ">LAKE</a>) with a Buy and lowers the price target from $28 to $23.

LAKE

DA Davidson Maintains Buy on Lakeland Industries, Lowers Price Target to $23

Mizuho analyst Siti Panigrahi maintains BILL Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>) with a Neutral and lowers the price target from $70 to $53.

BILL

Mizuho Maintains Neutral on BILL Holdings, Lowers Price Target to $53

- Dermata previously announced XYNGARI(TM) produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial -
- Additional data analysis revealed that XYNGARI(TM) separated from placebo after just four once-weekly treatments -
- XYNGARI(TM) could be the first once-weekly topical product candidate for moderate-to-severe acne -
SAN DIEGO, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / April 15, 2025 / <a href="https://pr.report/9972">Dermata Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRMA#NASDAQ">DRMA</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRMAW#NASDAQ">DRMAW</a>) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced that additional analysis of topline data from its Phase 3 STAR-1 trial showed that XYNGARI&#x2122; had a statistically significant difference from placebo on three efficacy endpoints as early as week 4, which occurred after just four treatments with XYNGARI&#x2122;.
XYNGARI&#x2122; Phase 3 STAR-1 Topline Week 4 Efficacy Results
In the intent to treat analysis, Dermata saw statistically significant differences in IGA treatment success, inflammatory lesion count, and non-inflammatory lesion count at week 4 (earliest measured timepoint) when compared to placebo.
Investigator Global Assessment: Patients achieving a 2-point reduction AND score of 0 or 1 ("clear" or "almost clear")
<figure class="table"> 
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>Week 4</td>
</tr>
<tr>
<td>XYNGARI&#x2122; (n=342)</td>
<td>11.9%</td>
</tr>
<tr>
<td>Placebo (n=178)</td>
<td>6.2%</td>
</tr>
<tr>
<td>p-value</td>
<td>p &lt; 0.05</td>
</tr>
</tbody>
</table>
</figure>
Mean change from baseline in inflammatory lesion count
<figure class="table"> 
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>Week 4</td>
</tr>
<tr>
<td>XYNGARI&#x2122; (n=342)</td>
<td>-11.4</td>
</tr>
<tr>
<td>Placebo (n=178)</td>
<td>-8.6</td>
</tr>
<tr>
<td>p-value</td>
<td>p &lt; 0.001</td>
</tr>
</tbody>
</table>
</figure>
Mean change from baseline in non-inflammatory lesion count
<figure class="table"> 
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>Week 4</td>
</tr>
<tr>
<td>XYNGARI&#x2122; (n=342)</td>
<td>-12.4</td>
</tr>
<tr>
<td>Placebo (n=178)</td>
<td>-8.8</td>
</tr>
<tr>
<td>p-value</td>
<td>p &lt; 0.001</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;

Biotech

General

DRMA

DRMAW

Dermata's XYNGARI Phase 3 Trial Hits Statistically Significant Difference At 4 Weeks

Mizuho analyst Matthew Broome maintains Bentley Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSY#NASDAQ">BSY</a>) with a Outperform and lowers the price target from $60 to $50.

Mizuho Maintains Outperform on Bentley Systems, Lowers Price Target to $50

Hannon Armstrong Sustainable Infrastructure Capital

HASI

HASI shares are trading lower after Baird cut its price target on the stock from $47 to $41.

DA Davidson analyst Peter Winter maintains M&amp;T Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>) with a Neutral and lowers the price target from $205 to $189.

DA Davidson Maintains Neutral on M&T Bank, Lowers Price Target to $189

Mizuho analyst Siti Panigrahi maintains Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) with a Outperform and lowers the price target from $400 to $350.

ADSK

Mizuho Maintains Outperform on Autodesk, Lowers Price Target to $350

A $500 billion commitment by Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) to build artificial intelligence supercomputers exclusively in the U.S. is drawing attention from Washington to Wall Street <a href="https://www.benzinga.com/news/econ-s">as reshoring trends accelerate.</a>
In a Tuesday post on Truth Social, President Donald Trump announced the move and said Nvidia will receive expedited permits for its ambitious U.S.-based AI infrastructure investment, calling it a "very big and exciting news."
The announcement comes amid a broader push from the Trump administration to accelerate domestic technology manufacturing and reduce reliance on China. Trump also pledged to expedite all necessary permits for other companies investing in what he dubbed the "Golden Age of America."
Over the weekend, the administration confirmed exemptions to new tariffs of up to 145% on critical tech imports such as smartphones and semiconductors—moves aimed at shielding U.S. tech leaders from global trade friction.
<h3 class="wp-block-heading">Bank of America Sees Earnings Tailwinds From Reshoring</h3>
In a note shared Monday, Bank of America semiconductor analyst Vivek Arya said earnings expectations for U.S.-based companies benefiting from reshoring remain on solid footing. 
"We expect earnings estimates from companies exposed to reshoring beneficiaries to remain well positioned to largely deliver on earnings expectations," Arya said.
Nvidia, in particular, was highlighted as a top sector pick alongside Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>), Marvell Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>), chip-design leaders Cadence Design Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) and Synopsys Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPS#NASDAQ">SNPS</a>) as well as semiconductor capital equipment makers Lam Research Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) and KLA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>).
Bank of America holds a $200 price target on Nvidia, implying an 80% upside from its current $110 share price. The bank values the stock at 33 times expected calendar year 2026 earnings, excluding cash—within its historical 25x to 56x forward price-to-earnings range.
According to Arya, this valuation is justified given Nvidia's broader exposure to long-term secular trends, including artificial intelligence infrastructure, gaming cycle recovery and robust data center demand.
<h3 class="wp-block-heading">Market Reactions</h3>
NVIDIA shares edged up 0.2% in premarket trading Tuesday, following a 0.2% dip on Monday. The stock has surged 28% since last week's lows, which were triggered by renewed tariff fears.
Top premarket risers within the iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) were KLA Corp., Onto Innovation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONTO#NASDAQ">ONTO</a>) and ASML Holding N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) with gains of about 1%. 
Read now: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44807995/us-stock-futures-waver-after-two-day-rally-trumps-tariff-moves-could-end-a-3-year-rolling-recession-says-expert">US Stock Futures Waver After Two-Day Rally: Trump&#8217;s Tariff Moves Could End A 3-Year &#8216;Rolling Recession,&#8217; Says Expert</a></li>
</ul>
Photo: Shutterstock

Government

Macro Economic Events

Regulations

Sector ETFs

Econ #s

Economics

Tech

ETFs

ASML

AVGO

KLAC

LRCX

MRVL

NVDA

ONTO

SNPS

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

Trump Hypes $500 Billion NVIDIA Investment In US AI Supercomputers: 'Golden Age Of America' Begins

Independent Data Safety Monitoring Board (DSMB) recommends that the study proceeds as designed based on 30-day data safety assessment of participants treated in low dosage group.
The company plans to progress the trial to enrollment of 39 participants in the United States.
SUNNYVALE, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc.&nbsp;(NASDAQ:<a href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the study's independent DSMB, which conducted a planned review of the 30-day safety data from the roll-in 20 million cell dosing cohort in the CardiALLO-HF trial, recommended that the study continue as designed. There have been no treatment emergent major adverse cardiac events observed nor has there been any clinical evidence of immune reactions to the allogeneic cells implanted.
"We are pleased with the DSMB's recommendation, an important step forward in advancing this allogeneic off the shelf mesenchymal stromal/stem cell therapy," said Peter Altman, BioCardia Chief Executive Officer. "Today's result has potential to be helpful with ongoing discussions around nondilutive funding and partnering opportunities for our MSC platform. Success in this trial can enable future pivotal trial design and funding in the USA, conditional time limited approval with reimbursement in Japan, as well as the advancement of CardiALLO MSC therapy for the likely orphan indications of pediatric and adult congenital heart disease."
Previous clinical results of MSC in ischemic heart failure from our co-sponsored TRIDENT trial1 demonstrated that higher MSC cell dosages reduced myocardial scar and increased left ventricular ejection fraction, and peer results2 have indicated that patients with active inflammation have sustained reduction in cardiovascular major morbidity. CardiALLO HF at high dosage is anticipated to have at least twice the effective dosage of these previous studies and will be the first trial to target patients with active inflammation.&nbsp;&nbsp;

BCDA

DSMB Recommends That Study On Biocardia's CardiALLO-HF Trial Proceeds As Designed Based On 30-day Data Safety Assessment Of Participants Treated In Low Dosage Group

CCEL

Cryo-Cell International Q1 2025 GAAP EPS $0.03 Beats $0.02 Estimate, Sales $7.97M Miss $8.04M Estimate

Stock Split

KZIA

Kazia Therapeutics To Change Ratio Of Its ADSs To Ordinary Shares From 1 ADS Representing 100 Ordinary Shares To 1 ADS Representing 500 Ordinary Shares

Mizuho analyst Siti Panigrahi maintains 8x8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGHT#NASDAQ">EGHT</a>) with a Underperform and lowers the price target from $2.5 to $2.

EGHT

Mizuho Maintains Underperform on 8x8, Lowers Price Target to $2

<ul>
<li>Execution of bolt-on acquisition strategy continues to enhance company's durable financial profile by adding highly complementary products and capabilities focused on high-growth, sustainable end markets</li>
<li>Acquisitions will expand Ingersoll Rand's product and technology portfolio with additional chiller and onsite gas generation offerings and support the company's in-region for the region strategy</li>
<li>Acquisitions have a combined pre-synergy Adjusted EBITDA purchase multiple of high-single digits &nbsp;</li>
</ul>
DAVIDSON, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Ingersoll Rand Inc., (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IR#NYSE">IR</a>) a global provider of mission-critical flow creation and life science and industrial solutions, has acquired G &amp; D Chillers, Inc. ("G &amp; D") and Advanced Gas Technologies Inc. ("AGT") for a combined purchase price of approximately $27 million to further grow the company's air treatment portfolio.
G &amp; D, headquartered in the United States, builds premium glycol chillers to cool liquids, especially in applications requiring temperatures below freezing, like in breweries, wineries, and food processing. G &amp; D expands Ingersoll Rand's manufacturing, engineering, and Engineer to Order (ETO) capabilities for chillers in the North American market.
AGT, headquartered in Ontario, Canada, is a custom designer and supplier of onsite gas generation systems serving industrial customers primarily in Canada. This acquisition adds new packaging capabilities and an established channel presence.
G &amp; D and AGT will both join the Industrial Technologies and Services segment (IT&amp;S).

Ingersoll Rand Further Enhances Air Treatment Capabilities With Two Acquisitions, G & D Chillers And Advanced Gas Technologies For A Combined Purchase Price Of ~$27M

Canaccord Genuity analyst Whitney Ijem maintains Verve Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>) with a Buy and raises the price target from $32 to $39.

Comments

BFF BK SPA by BFF BK SPA

Vendite allo scoperto

BFF BK SPA by BFF BK SPA (OTC:BFFBF) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO